A1LN34 Financial Statements From 2010 to 2024
| A1LN34 Stock | BRL 73.50 0.84 1.16% |
Check A1LN34 financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among A1LN34's main balance sheet or income statement drivers, such as , as well as many indicators such as . A1LN34 financial statements analysis is a perfect complement when working with A1LN34 Valuation or Volatility modules.
A1LN34 |
A1LN34 Company Current Valuation Analysis
A1LN34's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current A1LN34 Current Valuation | 5.15 B |
Most of A1LN34's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, A1LN34 is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, A1LN34 has a Current Valuation of 5.15 B. This is 64.14% lower than that of the Healthcare sector and 10.86% higher than that of the Biotechnology industry. The current valuation for all Brazil stocks is 69.02% higher than that of the company.
A1LN34 Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining A1LN34's current stock value. Our valuation model uses many indicators to compare A1LN34 value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across A1LN34 competition to find correlations between indicators driving A1LN34's intrinsic value. More Info.A1LN34 is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value A1LN34 by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for A1LN34's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About A1LN34 Financial Statements
A1LN34 stakeholders use historical fundamental indicators, such as A1LN34's revenue or net income, to determine how well the company is positioned to perform in the future. Although A1LN34 investors may analyze each financial statement separately, they are all interrelated. For example, changes in A1LN34's assets and liabilities are reflected in the revenues and expenses on A1LN34's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in A1LN34. Please read more on our technical analysis and fundamental analysis pages.
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference therapeutics. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. ALNYLAM PHARDRN operates under Biotechnology classification in Brazil and is traded on Sao Paolo Stock Exchange. It employs 1453 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in A1LN34 Stock
A1LN34 financial ratios help investors to determine whether A1LN34 Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in A1LN34 with respect to the benefits of owning A1LN34 security.